Gene · 6208
RPS14: ribosomal protein S14
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS14: ribosomal protein S14. Genes, record 6208. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6208
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P62263 | Small ribosomal subunit protein uS11 | 151 | 202 | Ensembl, GeneID, HGNC |
Source UniProt
Patents72
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 62083 | P62263 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62084 | P62263 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62085 | P62263 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 62086 | P62263 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4726 | P62263 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4862 | P62263 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4726 | P62263 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4862 | P62263 | Espacenet |
| JP 2024009871 A | 2024-01-23 | 57 | P62263 | Espacenet |
| JP 2023535604 A | 2023-08-18 | 3 | P62263 | Espacenet |
1 to 10 of 72
See all 72 patentsDrugs9
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATALUREN | CHEMBL256997 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| CITATUZUMAB BOGATOX | CHEMBL1743000 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| CYCLOHEXIMIDE | CHEMBL123292 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| DORLIMOMAB ARITOX | CHEMBL2109124 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ELX-02 | CHEMBL4297744 | 80S Ribosome modulator | MODULATOR | ChEMBL |
| MT-3724 | CHEMBL4297789 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TAPLITUMOMAB PAPTOX | CHEMBL2107890 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| TELIMOMAB ARITOX | CHEMBL2108790 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
| ZOLIMOMAB ARITOX | CHEMBL2108785 | 80S Ribosome inhibitor | INHIBITOR | ChEMBL |
Trials38
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07523581 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT05448755 | ELX-02 | PHASE2 | 2026-02-24 | ClinicalTrials.gov |
| NCT04336826 | ATALUREN | PHASE2 | 2024-04-01 | ClinicalTrials.gov |
| NCT04135495 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04126473 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04117880 | ATALUREN | PHASE2 | ClinicalTrials.gov | |
| NCT04069260 | ELX-02 | PHASE2 | ClinicalTrials.gov | |
| NCT04014530 | ATALUREN | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03796637 | ATALUREN | PHASE2 | 2022-04-05 | ClinicalTrials.gov |
| NCT03645395 | MT-3724 | PHASE2 | 2022-08-16 | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsNIH grants1,096
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS14 papers | Newest fiscal year |
|---|---|---|---|
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 7 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 4 | 2025 |
| R01CA200709 | Facilitated recruitment of MYC to chromatin by interaction with WDR5 | 4 | 2025 |
| P01CA108671 | Myeloproliferative Neoplasms-Research Consortium | 3 | 2025 |
| P30CA014599 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,096Source NIH's project files
See all 1,096 nih grantsPapers1,363
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cloning, expression, and purification of small subunit human ribosomal proteins SA/uS2, S2/uS5, S3/uS3, S7/eS7, S8/eS8, S12/eS12, S13/uS15, and S14/uS11 for in vitro characterization. | MicroPubl Biol | 2026 | 42502757 | PubTator, text mining | PubMed |
| S1-4 aptamer-mediated iron oxide nanoparticles for targeted magnetic hyperthermia in MCF-7 breast cancer cells. | J Int Med Res | 2026 | 42446548 | PubTator, text mining | PubMed |
| Proteomic profiling of cytoskeletal interactomes using MT-ID and Act-ID. | bioRxiv | 2026 | 42182354 | PubTator, text mining | PubMed |
| Proteomic mapping of Rosa damascena nanovesicles reveals plastid mitochondrial metabolic convergence and antimicrobial peptides. | Plant Signal Behav | 2026 | 41803707 | PubTator, text mining | PubMed |
| Nucleolus as a cornerstone linking proliferation and metabolism to cellular responses to stress: involvement of transcription factors MYC and p53. | Front Mol Biosci | 2026 | 41777667 | PubTator, text mining | PubMed |
| Manganese modulates hepatocellular carcinoma cytotoxicity and doxorubicin sensitivity in a dose dependent manner. | Front Oncol | 2026 | 41768239 | PubTator, text mining | PubMed |
| Mechanisms of the Antiproliferative Effects of SIRT6 Inhibition in Melanoma: A Multi-Omics Analysis. | Cancers (Basel) | 2026 | 41749843 | PubTator, text mining | PubMed |
| Proteomic Insights into Heroin Use: Links to Neurodegeneration. | Mol Neurobiol | 2026 | 41721130 | PubTator, text mining | PubMed |
| Single-Cell RNAseq Identifies Heterogeneity in Myoblasts From Older Adults With Differences Related to Muscle Mass and Function. | J Cachexia Sarcopenia Muscle | 2026 | 41703779 | PubTator, text mining | PubMed |
| Mass spectrometry-based human spatial omics: fundamentals, innovations, and applications. | J Biomed Sci | 2026 | 41645178 | PubTator, text mining | PubMed |
1 to 10 of 1,363
See all 1,363 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6208
GET https://conductscience.org/api/genes/v1/6208/patents?page=2